Dicerna Pharmaceuticals reported $-29107000 in EBIT for its first fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebit Change
Acceleron Pharma XLRN:US $ -63603000 6.01M
Agenus AGEN:US $ -41371000 16.23M
Alnylam Pharmaceuticals ALNY:US $ -186254000 7.97M
Amgen AMGN:US $ 2129M 121M
Arrowhead Research ARWR:US $ -28232000 4.18M
Biogen BIIB:US $ 1042.4M 1208.7M
Bluebird Bio BLUE:US $ -230839000 25.98M
Dicerna Pharmaceuticals DRNA:US $ -29107000 2.54M
Gilead Sciences GILD:US $ 2912M 261M
GlaxoSmithKline GSK:LN 1.68B 59M
Immunogen IMGN:US $ -28916000 65.4M
Intercept Pharmaceuticals ICPT:US $ -29190000 10.8M
Intrexon XON:US $ -17688000 807K
Karyopharm Therapeutics KPTI:US $ -52373000 15.31M
Lexicon Pharmaceuticals LXRX:US -20839000 13.61M
Macrogenics MGNX:US $ -51293000 49.12M
Merk MRK:US $ 4290M 4007M
Mirati Therapeutics MRTX:US $ -132421000 26.09M
Pfizer PFE:US $ 5757M 4605M
Regeneron Pharmaceuticals REGN:US $ 1112.7M 54.3M
Ultragenyx Pharmaceutical RARE:US $ -106569000 10.49M